In Italy, the classes under consideration include GLP-1 receptor agonists (dulaglutide, exenatide, exenatide LAR, liraglutide, lixisenatide, semaglutide) and also GIP/GLP-1 dual agonists (tirzepatide)
5.4 Weight Loss in Non-Obese Individuals (Clinical Considerations) Use in non-obese populations is controversial
Storage Guide Introduction Managing a new medication can feel overwhelming, especially when that medication is a central part of your weight loss journey
Key Research Highlights Triple GLP-1, GIP, and glucagon receptor activity Metabolic pathway and energy expenditure research Appetite and satiety signaling studies Hepatic lipid metabolism investigations Cardiovascular biomarker research Frequently studied alongside MOTS-c Research Applications of Retatrutide Retatrutide has emerged as one of the most promising compounds in metabolic research due to its unique ability to activate GLP-1, GIP, and glucagon receptors simultaneously
Animal and clinical studies have shown that GLP-1RAs ameliorate liver inflammation and lower the risk of NAFLD and NASH developing into liver cancer
Mental Health Effects of Tirzepatide Tirzepatide, a dual GLP-1/GIP receptor agonist , is primarily used for managing type 2 diabetes and weight loss